Moreadith Randall 4

What Happened

• Moreadith Randall, Chief Scientific Officer of Serina Therapeutics (SER), exercised stock options and sold shares on 2026-01-22. She exercised 2,500 options at $0.06 per share (cost $150) to acquire shares and sold 2,500 shares in an open-market sale at $2.95 per share for proceeds of $7,375. A separate derivative conversion of 2,500 shares is also reported as a disposition at $0.00.
• Net proceeds from the exercise plus sale (sale proceeds minus exercise cost) were approximately $7,225. The filing does not state a reason for the transactions.

Key Details

• Transaction dates/prices:
  • 2026-01-22: Exercise (M) — 2,500 shares @ $0.06 (cost $150, acquired)
  • 2026-01-22: Sale (S) — 2,500 shares @ $2.95 (proceeds $7,375, disposed)
  • 2026-01-22: Exercise/conversion (M) — 2,500 shares @ $0.00 (disposed)
• Shares owned after transaction: Not provided in the supplied report data.
• Footnote: F1 — the stock options are fully vested.
• Filing date: 2026-01-23 (report covers transactions on 2026-01-22); filing appears timely based on provided dates.

Context

• This combination of option exercise and same-day sale is commonly reported when insiders exercise options and sell some or all resulting shares; the filing itself does not state the purpose (e.g., cover exercise cost, taxes, or personal liquidity).
• The derivative entry reported as disposed at $0.00 likely reflects a non-cash conversion/adjustment; the Form 4 lists it as an exercise/conversion (M) but provides no cash amount.